Product Description

Mitoxantrone is a potent inhibitor of topoisomerase II and also inhibits protein kinase C (PKC). It demonstrates anti-tumor activity by inducing apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Additionally, mitoxantrone exhibits anti-orthopoxvirus activity.

Screeningbio‘s A549/Mitoxantrone resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Target Background

Mitoxantrone is a synthetic anthracenedione chemotherapeutic agent that functions as a topoisomerase II inhibitor. It intercalates into DNA and induces DNA strand breaks by stabilizing the topoisomerase II-DNA cleavable complex, leading to inhibition of DNA replication and transcription, cell cycle arrest, and apoptosis in rapidly dividing cancer cells. It is widely used in the treatment of acute myeloid leukemia, breast cancer, non‑Hodgkin lymphoma, and advanced prostate cancer. However, the development of drug resistance remains a major challenge limiting its long‑term efficacy.

Mechanistically, mitoxantrone resistance arises through multiple cellular adaptations. Reduced expression or mutations in topoisomerase II isoforms (mainly TOP2A and TOP2B) decrease drug target availability and binding affinity, while upregulation of efflux transporters such as P‑glycoprotein (MDR1/ABCB1) and ABCG2 (BCRP) significantly decreases intracellular drug accumulation. Additionally, activation of survival pathways—including PI3K/Akt, MAPK, and NF‑κB signaling—promotes anti‑apoptotic responses. Enhanced DNA repair capacity (e.g., homologous recombination and NHEJ pathways), changes in drug‑metabolizing enzymes, and enhanced autophagy or epithelial–mesenchymal transition (EMT) also contribute to reduced drug sensitivity.

Understanding these mechanisms is critical for designing strategies to overcome resistance, such as combination therapy with ABC transporter inhibitors, targeting compensatory signaling networks, suppressing DNA repair mechanisms (e.g., using PARP inhibitors), or employing patient‑derived resistant cell models to guide personalized therapy development.